Cevec Archives

News and Trends 24 Jul 2017

How can Recombinant Proteins be used in Veterinary Medicine?

This expert has told us why recombinant proteins are an elegant way to go in the production of veterinary vaccines and why glycosylation patterns can play a big part in all of it! For many decades, human blood plasma has been a source of different biotherapeutic proteins, including antibodies, albumin and blood coagulation factors. Although they are […]

July 24, 2017 - 5 minutesmins - By External Contributor

News and Trends 20 Feb 2017

CEVEC is Transforming Vaccine Development starting with Zika

CEVEC Pharmaceuticals recently partnered up with NewLink Genetics to use its CAP technology for the development of new vaccines against the Zika virus. We had the opportunity to ask CEVECs CSO a few questions about how their technology can transform vaccine development. CEVEC Pharmaceuticals is developing high-quality platforms for the efficient and safe production of glycosylated proteins, viral vaccines and […]

February 20, 2017 - 6 minutesmins - By External Contributor

News and Trends 16 Nov 2016

Meet the CEO making the Next Generation of Gene Therapies Possible

How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success. The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors […]

November 16, 2016 - 6 minutesmins - By External Contributor

News and Trends 3 Nov 2016

CEVEC is Revolutionizing Industrial Protein & Viral Vector Production

CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins. CEVEC is a Biotech with the mission of raising the industrial standard for the large-scale production of glycosylated proteins, viral vaccines and gene therapy […]

November 3, 2016 - 2 minutesmins - By External Contributor

News and Trends 19 Oct 2016

This Technology Opens new Horizons for Protein Production

Based in Cologne, Germany, Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors. Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is […]

October 19, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 1 Sep 2016

Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”

Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. I had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy. Gene therapy is one of the strongest trends in biotechnology right now. The field has […]

September 1, 2016 - 6 minutesmins - By Denise Neves Gameiro

cevec virus gene therapy paragon manufacture

News and Trends 7 Jun 2016

German Biotech partners up in the US for scalable viral vector production in Gene Therapy

Cevec is joining forces with US-based Paragon. The objective is to make Cevec’s scalable CAP expression technology the industry standard for glycoproteins and viral vectors in gene therapies. Based in Cologne (Germany), Cevec tackles with its human cell-based expression systems (CAP-GT and CAP-Go) two big challenges in Biotech manufacturing – industrial scale production of viral vectors […]

June 7, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 5 Jul 2015

CEVEC and Biotest to ease hemophilia patients’ lifes

A German collaboration seeks to treat the symptoms of hemophilia in patients suffering from the later. CEVEC and Biotest will join forces to produce and commercialize molecules using CEVEC’s expression platform. Biotest develops immunoglobulins, coagulation factors and albumins, based on human blood plasma, used for diseases of the immune and hematopoietic system. This makes it […]

July 5, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us